These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 35131510)

  • 21. Anti-epithelial-derived cytokines for severe asthma: Systematic review and meta-analysis.
    Su J; Pitre T; Desai K; Mah J; Nair P; Ho T; Zeraatkar D
    J Allergy Clin Immunol; 2023 Jun; 151(6):1566-1576. PubMed ID: 36871917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biologics in severe asthma.
    Pelaia C; Pelaia G; Crimi C; Longhini F; Lombardo N; Savino R; Sciacqua A; Vatrella A
    Minerva Med; 2022 Feb; 113(1):51-62. PubMed ID: 33555158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab.
    van Dijk YE; Rutjes NW; Golebski K; Şahin H; Hashimoto S; Maitland-van der Zee AH; Vijverberg SJH
    Paediatr Drugs; 2023 Nov; 25(6):677-693. PubMed ID: 37658954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eosinophilic respiratory disorders and the impact of biologics.
    Bernstein JS; Wechsler ME
    Curr Opin Pulm Med; 2023 May; 29(3):202-208. PubMed ID: 36866734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biologics in the treatment of asthma in children and adolescents.
    Bacharier LB; Jackson DJ
    J Allergy Clin Immunol; 2023 Mar; 151(3):581-589. PubMed ID: 36702649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Biologic Therapy on the Small Airways Asthma Phenotype.
    Chan R; Lipworth BJ
    Lung; 2022 Dec; 200(6):691-696. PubMed ID: 36239786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dupilumab Efficacy in Patients With Uncontrolled or Oral Corticosteroid-Dependent Allergic and Nonallergic Asthma.
    Brusselle G; Quirce S; Papi A; Kuna P; Chipps BE; Hanania NA; Blaiss M; Msihid J; Jacob-Nara JA; Deniz Y; Rowe PJ; Gall R; Ortiz B; Djandji M; Radwan A
    J Allergy Clin Immunol Pract; 2023 Mar; 11(3):873-884.e11. PubMed ID: 36572184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Choice of biologics in asthma endotypes.
    Wangberg H; Woessner K
    Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):79-85. PubMed ID: 33306486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Positioning of Tezepelumab in Severe Asthma.
    Miralles-López JC; Antolín-Amérigo D; García-Moguel I; Domínguez-Ortega J; Delgado-Romero J; Quirce S
    J Investig Allergol Clin Immunol; 2024 Feb; 34(1):1-11. PubMed ID: 37812191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mechanism of action of tezepelumab (TEZSPIRE
    Niu M; Yabuta T; Makita N
    Nihon Yakurigaku Zasshi; 2024; 159(1):53-60. PubMed ID: 38171840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tezepelumab in patients with allergic and eosinophilic asthma.
    Caminati M; Buhl R; Corren J; Hanania NA; Kim H; Korn S; Lommatzsch M; Martin N; Matucci A; Nasser SM; Pavord ID; Domingo C
    Allergy; 2024 May; 79(5):1134-1145. PubMed ID: 38146651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment.
    Latorre M; Bacci E; Seccia V; Bartoli ML; Cardini C; Cianchetti S; Cristofani L; Di Franco A; Miccoli M; Puxeddu I; Celi A; Paggiaro P
    Ther Adv Respir Dis; 2020; 14():1753466620965151. PubMed ID: 33263506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term multicenter comparison shows equivalent efficacy of monoclonal antibodies in severe asthma therapy.
    Kayser MZ; Suhling H; Fuge J; Hinze CA; Drick N; Kneidinger N; Behr J; Taube C; Welte T; Haasler I; Milger K
    BMC Pulm Med; 2024 Mar; 24(1):149. PubMed ID: 38515071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of biologic therapy on airway hyperresponsiveness in asthma.
    Chan R; Lipworth B
    Ann Allergy Asthma Immunol; 2023 Jul; 131(1):37-41. PubMed ID: 36841374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antialarmins for treatment of asthma: future perspectives.
    Al-Sajee D; Oliveria JP; Sehmi R; Gauvreau GM
    Curr Opin Pulm Med; 2018 Jan; 24(1):32-41. PubMed ID: 29084017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity of biologics used in the treatment of asthma.
    Neunie OAM; Rabbani W; Baker D; Chambers ES; Pfeffer PE; Kang AS
    Hum Antibodies; 2024; 32(3):121-128. PubMed ID: 38905039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma.
    Ly N; Zheng Y; Griffiths JM; van der Merwe R; Agoram B; Parnes JR; Roskos L
    J Clin Pharmacol; 2021 Jul; 61(7):901-912. PubMed ID: 33368307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tezepelumab: patient selection and place in therapy in severe asthma.
    Menzella F; Munari S; Corsi L; Tonin S; Cestaro W; Ballarin A; Floriani A; Dartora C; Senna G
    J Int Med Res; 2024 Apr; 52(4):3000605241246740. PubMed ID: 38676539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of Biologics in Asthma.
    McGregor MC; Krings JG; Nair P; Castro M
    Am J Respir Crit Care Med; 2019 Feb; 199(4):433-445. PubMed ID: 30525902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma.
    Pelaia C; Pelaia G; Longhini F; Crimi C; Calabrese C; Gallelli L; Sciacqua A; Vatrella A
    Biomedicines; 2021 Aug; 9(9):. PubMed ID: 34572294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.